Reuters logo
BRIEF-Paratek Pharma, Zai Lab announce agreement
2017年4月24日 / 上午11点20分 / 7 个月前

BRIEF-Paratek Pharma, Zai Lab announce agreement

April 24 (Reuters) - Paratek Pharmaceuticals Inc:

* Paratek Pharmaceuticals and Zai Lab announce collaboration, development and license agreement for omadacycline in China

* Paratek Pharmaceuticals Inc - under deal, co granted to Zai Lab exclusive license to develop, manufacture, commercialize omadacycline

* Paratek Pharmaceuticals Inc - deal terms covers territories for omadacycline for Greater China Territory, Hong Kong, Macau, and Taiwan markets

* Paratek Pharmaceuticals Inc - companies will establish joint steering committee to review, oversee all development, manufacturing, commercialization plans

* Paratek Pharmaceuticals Inc - Paratek will receive a $7.5 million upfront payment in connection with signing of agreement

* Paratek Pharmaceuticals Inc - Allergan has publicly announced plans to submit an NDA in U.S. In second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below